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Abstract
Background: Annually, there are approximately 25 million unsafe abortions, and this remains a leading cause of maternal
morbidity and mortality. In settings where abortion is restricted, women are increasingly able to self-manage abortions by
purchasing abortion medications such as misoprostol and mifepristone (RU-486) from pharmacies or other drug sellers. Better
availability of these drugs has been shown to be associated with reductions in complications from unsafe abortions. In Bangladesh,
abortion is restricted; however, menstrual regulation (MR) was introduced in the 1970s as an interim method of preventing
pregnancy. Pharmacy provision of medications for MR is widespread, but customers purchasing these drugs from pharmacies
often do not have access to quality information on dosage and potential complications.
Objective: This study aimed to describe a call center intervention in Bangladesh, and assess call center use over time and how
this changed when a new MR product (combined mifepristone-misoprostol) was introduced into the market.
Methods: In 2010, Marie Stopes Bangladesh established a care provider–assisted call center to reduce potential harm from
self-administration of MR medications. The call center number was advertised widely in pharmacies and on MR product packaging.
We conducted a secondary analysis of routine data collected by call center workers between July 2012 and August 2016. We
investigated the reported types of callers, the reason for call, and reported usage of MR products before and after November 2014.
We used an interrupted time series (ITS) analysis to formally assess levels of change in caller characteristics and reasons for
calling.
Results: Over the 4-year period, 287,095 calls about MR were received and the number of users steadily increased over time.
The most common callers (of 287,042 callers) were MR users (67,438, 23.49%), their husbands (65,999, 22.99%), pharmacy
workers (65,828, 22.93%), and village doctors (56,036, 19.52%). Most MR calls were about misoprostol, but after November
2014, a growing proportion of calls were about the mifepristone-misoprostol regimen. The most common reasons (of 287,042
reasons) for calling were to obtain information about the regimen (208,605, 72.66%), to obtain information about side effects
(208,267, 72.54%), or to report side effects (49,930, 17.39%). The ITS analyses showed that after November 2014, an increasing
number of calls were from MR users who had taken the complete regimen (P=.02 and who were calling to discuss reported side
effects (P=.01) and pain medication (P=.01), and there were fewer calls asking about dosages (P<.001).
Conclusions: The high call volume suggests that this call center intervention addressed an unmet demand for information about
MR medications from both MR users and health care providers. Call center interventions may improve the quality of information
available by providing information directly to MR users and drug sellers, and thus reducing the potential harm from self-management
of MR medications.
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Introduction
Background
The most recent estimates suggest that between 2010 and 2014,
there were 56 million abortions annually, of which 25 million
were unsafe [1]. Unsafe abortions are a leading cause of
maternal morbidity and mortality and are particularly prevalent
in low-income settings. In settings where abortion is restricted
or difficult to access, women are increasingly able to
self-manage abortions more safely by purchasing abortion
medications such as misoprostol and mifepristone from
pharmacies or other drug sellers [2,3]. The increasing
availability of these medications is thought to have resulted in
reduced morbidity from unsafe self-induced abortion in many
low-income countries [4-6]. The World Health Organization’s
(WHO) guidance on health worker roles for safe abortion states
that women can safely self-manage elements of medical abortion
in circumstances where women have a source of accurate
information and access to a health care provider should they
need or want it [7]. However, women accessing these
medications from pharmacies often do not receive adequate
information from pharmacy workers because pharmacy staff
lack knowledge about effective regimens and potential
complications [2,3].
The increasing use of mobile and wireless technologies for
health—known as mobile health (mHealth)—has huge potential
to improve health systems in low- and middle-income countries
(LMICs) through better access to knowledge and information
[8]. mHealth approaches are being promoted in Bangladesh,
where household mobile phone ownership has risen rapidly
from 32% of households in 2007 to 89% in 2014 [9,10]. Call
centers and hot lines can help to reduce geographic inequalities
in health services and may be particularly appropriate for
reproductive health issues because they can provide client
anonymity when discussing sensitive matters. Recent studies
have demonstrated the importance of hotlines for enabling
women’s access to information on safe abortion medications in
legally restrictive settings such as Latin America and Indonesia
[11,12], and safe abortion hotlines exist in more than 20
countries in the global South [13]. Furthermore, it has been
shown that mHealth approaches (involving getting advice and
support by phone or the internet) can be successfully used by
women self-administering medical abortions [14]. However, it
is recognized that more research is needed to understand exactly
how women use abortion hotlines for support and for what
reasons [15].
The Context of Menstrual Regulation in Bangladesh
In Bangladesh, abortion is legal only to save a woman’s life;
however, menstrual regulation (MR), “an interim method of
establishing non-pregnancy in women at risk of being pregnant,”
was introduced in the country in 1972 as a strategy to reduce
morbidity and mortality from unsafe abortion [16]. Pregnancy
is not confirmed before administering the procedure or
medications. The approved methods for MR services are manual
vacuum aspiration (MVA) up to 12 weeks after a missed period
and, since 2013, administration of mifepristone and misoprostol
up to 9 weeks [17]. In February 2013, the first combination
pack of mifepristone-misoprostol (branded the MM Kit) was
accepted by the National Drug Administration of Bangladesh
and came onto the market as an alternative to surgical MR. A
second brand, the MTP Kit, was approved and became available
later in the year [18]. Self-induced MR with medication has
also long been practiced in Bangladesh through off-label use
of misoprostol, which is registered for use for postpartum
hemorrhage and peptic ulcer, provided through pharmacies [19].
There is little regulation of pharmacies in Bangladesh, and many
medications are sold over the counter without a prescription
[20], including misoprostol and MR medications [19,21]. Since
the registration of the combination pack of
mifepristone-misoprostol, combination products as well as
misoprostol alone have increasingly become available in
pharmacies [21]. Information provided by the Directorate
General of Drug Administration in Bangladesh shows that
currently 32 brands of misoprostol only are registered for sale
by 28 pharmaceutical companies, and the combination regimen
is registered for sale by at least 8 different companies [22].
However, as seen in other countries, pharmacy and mystery
client surveys conducted in Bangladesh have documented poor
knowledge of effective regimens for medical MR among
pharmacy workers [19,21,23]. This is particularly important,
given that misoprostol is not registered for MR and does not
contain instructions for use for this indication.
The most recent study of MR incidence in Bangladesh showed
that in 2014, an estimated 430,000 MR procedures (using MVA
or medication) were performed in health facilities nationwide,
whereas an estimated 1,194,000 induced abortions occurred and
257,000 women were treated for complications from abortion
[24]. Singh et al found that of the women presenting with
postabortion complications, the proportion of women with
hemorrhage increased substantially between 2010 and 2014,
from 27% to 48%, and the estimated proportion with incomplete
abortion declined from 66% to 56% [24]. This is consistent with
a pattern of increased use of misoprostol-induced abortion, in
which heavy and prolonged bleeding is a common side effect.
It is possible that this symptom would have resolved without
further treatment for some women, but the trend suggests the
need for improved access to information about correct use and
potential side effects and complication management.
The Marie Stopes Bangladesh Call Center Initiative
and Aims of the Study
Marie Stopes Bangladesh (MSB) is a sexual and reproductive
health service provider, operating through 600 service delivery
outlets across all 64 districts of Bangladesh, including static
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centers, outreach teams accessing hard-to-reach and underserved
rural communities, public sector support, and social marketing
channels. To address the lack of access to accurate information
about MR medications, MSB set up a call center in 2010 with
the goal of preventing potential harm for individuals who
purchase MR medications from pharmacies and drug shops.
This study uses routine data to investigate the changing use of
the call center over a 4-year period (2012-2016). The objectives
of the study were to (1) describe the characteristics of call center
users and their reasons for calling and (2) assess whether the
introduction of a mifepristone-misoprostol combined regimen
into the market led to a change in the usage of the call center.
It is hoped that the results can inform future programming for
information provision about mifepristone and misoprostol in
Bangladesh and other LMICs. The term pharmacy can refer to
a range of businesses of various sizes and legal statuses, and in
this paper, we refer to pharmacies and drug shops as any outlet
whose business is selling medicines, regardless of their training,
staff qualifications, or legal status. We refer to
mifepristone-misoprostol and misoprostol alone as MR
medications for the remainder of the paper.
Methods
Details of the Call Center Initiative
This call center initiative is one of 27 reproductive health call
centers supported by Marie Stopes International worldwide
[25]. The call center provides a supplementary information
service for MR users and is open 24 hours a day, 7 days a week.
The call charge is at the rate of a regular call to a mobile phone,
but callers can also request an immediate free callback. The call
operators are all female, mid-level medical service providers
who have completed a 36-month course from the Medical
Assistant Training School. All operators receive in-house
training covering counseling skills for MR and related
reproductive health topics, MSB services, the use of medication
for MR, management of side effects and complications, referring
to the nearest private or public facility, and the legal status of
MR. The operators are also trained to discuss contraceptive
options with callers who have used or are intending to use
medications for MR. Regular refresher training sessions are
conducted for call operators. The quality of calls is routinely
monitored using mystery callers. The call center number is
widely promoted through a variety of channels; MSB distributes
promotional stickers, wallet-sized cards, and posters through
pharmacies and village doctors and promotes the call center
verbally when attending pharmacies and during orientations of
drug sellers and village doctors (eg, see Figure 1). In addition,
the call center number was printed on the packaging and foil of
2 MSB products (one misoprostol only from 2012 and another
combination pack [mifepristone-misoprostol] from 2014) and
a non-MSB combination pack product from 2015.
Figure 1. Examples of call centre promotional materials.
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Data
This study retrospectively analyzed routine data collected by
MSB call center operators between July 2012 and August 2016.
In June 2012, a 15-item monitoring form was designed to collect
information on the profile of callers and their reasons for calling.
All operators were trained to administer the questions from the
monitoring form during every call, to record responses on paper
during the call or immediately after, and to enter the data into
an Epi Info 7 database (developed by the Centers for Disease
Control and Prevention) between calls. No identifying
information such as the caller’s name or address was collected.
Each caller was asked if they had called before but repeat callers
are treated as distinct individuals and their records from previous
calls are not matched. Data collection commenced in July 2012
and is ongoing.
Variables and Analysis
The variables in the monitoring form are as follows. Callers
were asked about their location (one of several divisions of
Bangladesh), the age range of the MR user (in 5-year groups),
and whether they were a repeat caller (yes or no). Operators
recorded the caller’s relationship to the MR user with the
following response options: pharmaceutical representative,
pharmacist, pharmacy worker, village doctor, woman herself
(MR user), husband, mother, and other relative or friend of MR
user). All callers were asked the general reason for calling, and
the call center operator could select multiple responses from a
list of 12 (including misoprostol for medical MR, misoprostol
for other conditions, combination regimen for medical MR,
family planning, other reproductive or general health questions,
or information on the nearest clinic or hospital). If the call was
MR related, the specific queries of the caller were recorded
(including whether misoprostol can be used for medical MR,
correct dosage for medical MR [timing, dosage, or route],
questions about side effects and complications, experience of
side effects, experience of complications, taken the wrong dose,
pain medications, and accessing the clinic or hospital). If the
reason for calling was that the end user was experiencing side
effects or suspected complications, the types of side effects and
suspected complications were recorded. Complications are
reported as suspected because they were diagnosed remotely
by the call center operator based on information given by the
caller and may not be clinically accurate. MR-related callers
were asked whether the MR drug had already been purchased,
the brand purchased, and whether the end user had already taken
the medication.
Some adaptations were made to the monitoring form after the
initiation of data being recorded: the repeat caller variable was
only included from July 2013, whether the MR drug had already
been purchased was only available from November 2014, brand
data were available only from September 2013, and under
general reasons for calling, the response options
mifepristone-misoprostol combination pack, general health,
and other reproductive health were only available from
November 2014. The analysis received ethical approval from
the Marie Stopes Independent Ethics Review Committee
(012 15) and the Bangladesh Medical Research Council (803).
The ethics committee approved our analysis of routine data
without explicit consent from the participants to use their data
for research purposes, for the following reasons: (1) the risks
of identification of callers is minimal, especially as all data are
presented in aggregate, (2) the data were not part of a research
project but part of routine monitoring, and (3) the medications
used were part of a national protocol rather than being
introduced as part of the study.
Statistical Analysis
Use of the Call Center
We conducted descriptive analyses of the number of calls,
profiles of call center users, and their reported reasons for calling
over time, using aggregate monthly data.
Differences in Call Center Use
To assess whether the introduction of the combination regimen
was associated with differences in call center use, we compared
caller characteristics before and after November 2014. This
month was chosen because it was when the call center number
started to be printed on a combination pack, so although the
combination regimen was available on the market from March
2013, the call center was unlikely to receive calls until the call
center number was widely advertised through product
packaging. Interrupted time series (ITS) analysis was used [26]
to formally evaluate whether changes in the number of calls
according to reason for calling and caller type had occurred
after November 2014. We necessarily restricted the ITS to
outcomes that had complete data across the entire period. As
MR combination regimen users receive more comprehensive
dosage instructions from the packaging than MR
misoprostol-only users, we hypothesized that the introduction
of the combination regimen would result in a change in both
the level and slope of the relationship between types of callers,
reason for calling, and whether the MR user had taken the drug
before calling in the pre- and postintervention periods. We
conducted the ITS analysis using STATA 14.0 [27] using the
STATA module ITSA: Stata module to perform ITS analysis
for single and multiple groups [28].
Misoprostol-Only and Combination Regimen Callers
We also compared characteristics of calls related to misoprostol
only and the combination pack using bivariate crosstabulations.
Results
Use of the Call Center
A total of 344,827 calls were made to the call center between
July 2012 and August 2016, and the number of calls per month
increased from 2778 in July 2012 to a peak of 11,157 calls in
March 2016, falling to 8516 in August 2016 (Figure 2). Over
the whole period studied, 83.25% of the calls were about MR
(either misoprostol or combination regimen; n=287,095).
Between July 2012 and October 2014, all MR calls were about
misoprostol, but after the introduction of the call center number
to a combination pack in November 2014, calls about the
combination regimen grew rapidly and quickly overtook the
number of calls about misoprostol only MR.
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Figure 2. Number of calls received by the Marie Stopes Bangladesh call center, July 2012 to August 2016. MR: menstrual regulation.
The number and proportion of calls that were for non-MR
queries also increased after November 2014, and by August
2016, they accounted for a quarter of all calls. Non–MR-related
reasons for calling included questions about accessing the
nearest clinic or hospital (28,554/344,827, 8.28%), family
planning (6403/344,827, 3.10%), other reproductive or general
health topics (7156/344,827, 3.47%), misoprostol for other
indications (1518/344,827, 0.49%), and other reasons
(21,114/344,827, 10.06%). Non–MR-related calls are excluded
from the subsequent analysis.
Characteristics of Those Calling About Menstrual
Regulation
The characteristics of MR-related calls are shown in Table 1.
Over half (163,018, 56.79%) of the 287,042 MR-related calls
were made by MR users, their friends, or relatives: 67,438
(23.49%) from the MR user, 65,999 (22.99%) from their
husbands, 17,115 (5.99%) from their mother or other relatives,
and 12,446 (4.34%) from friends. Health care or medication
providers represented 123,467 (43.01%) of calls, 65,828
(22.93%) were from pharmacists or pharmacy workers, 56,036
(19.52%) of calls were from village doctors, and a small number
of calls (1603, 0.56%) were received from pharmaceutical
representatives. Most calls (141,148, 49.17%) came from the
two most populous divisions of Bangladesh, Dhaka and
Chittagong. The majority of callers reported the MR user’s age
as being below 25 years.
Just under half of MR calls (110,635/250,814, 44.94%) were
from repeat callers. We cross-tabulated repeat callers with other
characteristics (results available on request) and found that
repeat callers were more likely to be MR users or pharmacy
workers compared with calls from first-time callers, but there
were no other significant differences in the characteristics of
repeat callers and first-time callers. We also cross-tabulated the
reason for calling with the type of caller, which showed that
that calls about misoprostol for indications other than MR (eg,
related to postpartum hemorrhage) were more likely to be made
by a provider (predominantly driven by calls from village
doctors) than an MR user or their family.
Of 287,095 calls, 109,429 (64.50%) calls were made when the
MR user had already purchased the drug, and 68,732 (23.95%)
of the MR users had taken MR medications before calling. The
most common MR-related reasons for calling were to ask if
medications could be used for MR (161,145/169,453, 96.75%),
to obtain regimen information (208,605/287,095, 72.66%), and
to get information about side effects (208,267,287,095, 72.54%).
Overall, 49,930 of 287,095 people (17.39%) called because they
were experiencing side effects, 21,207 (7.39%, 21,207/218,738)
called to ask about pain medication, 6745 (3.08%,
6745/218,738) suspected they had taken the wrong dose, and
11,207 (3.90%, 11,207/287,095) wanted information on
accessing the nearest clinic or hospital. The most common side
effects reported were cramps (7.26%) followed by bleeding
(4.06%) and diarrhea (4.10%), fever (2.84%), and vomiting
(1.14%; data not shown). In addition, 2.83% of MR callers said
they thought they were experiencing complications, and almost
all of these were suspected to have incomplete MR. Only 3
callers reported excessive blood loss. Most callers called for
more than one reason.
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Table 1. Characteristics of individuals calling the Marie Stopes Bangladesh call center about menstrual regulation (MR) from July 2012 to August
2016.
P valueTotal, n (%)November 2014-
August 2016, %
July 2012-October
2014, %
Characteristic of the call or caller
<.001Type of caller
1603 (0.56)0.590.51Pharmaceutical representative
65,828 (22.93)23.7021.83Pharmacist or pharmacy worker
56,036 (19.52)18.6720.76Village doctor
67,438 (23.49)24.7421.70MR user (woman)
65,999 (22.99)19.3928.19Husband of MR user
17,115 (5.96)7.274.08Mother or other relative of MR user
12,466 (4.34)5.542.61Friend of MR user
557 (0.19)0.100.33Don’t know, refuse and missing
<.001Reported age of MR user (years)
67,579 (23.54)25.8520.20<20
106,453 (37.08)35.0340.0420-24
66,074 (23.01)21.1825.6725-29
35,188 (12.26)14.359.2430 or older
11,801 (4.11)3.604.85Don’t know, refuse and missing
<.001Division of Bangladesh
79,700 (27.76)27.2728.47Dhaka
33,870 (11.80)12.5410.72Rajshahi
28,175 (9.81)10.379.01Rangpur
61,448 (21.40)20.8422.21Chittagong
29,422 (10.25)11.258.80Sylhet
23,017 (8.02)7.738.44Khulna
19,758 (6.88)7.096.58Barisal
11,705 (4.08)2.915.76Out of country, don’t know, refuse and missing
<.001Repeat callera
23,450 (9.53)8.2112.44Don’t know and refuse
110,635 (44.94)44.6145.69Yes
112,085 (45.53)47.1841.87No
—
cMR user had purchased drug before callingb
1070 (0.63)——Don’t know and refuse
109,429 (64.50)——Yes
59,158 (34.87)——No
<.001MR user had taken drug before calling
44,745 (15.59)17.8012.38Taken complete regimen
23,987 (8.36)7.1010.17Started the regimen
208,211 (72.52)72.3572.78Not taken
10,152 (3.54)2.754.67Don’t know and other
Specific MR-related queryd
—164,145 (96.75)96.75—Whether misoprostol used for MRe
<.001208,605 (72.66)72.3573.11Correct MR dosage and regimenf
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P valueTotal, n (%)November 2014-
August 2016, %
July 2012-October
2014, %
Characteristic of the call or caller
<.001208,267 (72.54)72.3572.82Information on side effects and complications
<.00149,930 (17.39)18.9615.12Experiencing side effects
<.0018118 (2.83)3.372.04Caller suspects complications
<.0016745 (3.08)2.754.22Caller thinks they have taken the wrong doseg
<.00121,207 (7.39)7.836.75Questions about taking pain medication
<.00111,207 (3.90)5.881.04Questions about accessing clinic or hospital
—287,095 (100.00)59.0940.91Total
aQuestion introduced in July 2013.
bMissing data due to question being introduced in November 2014.
cNot applicable.
dMultiple responses allowed, so column percentages can total more than 100.
eMissing data due to question being introduced in November 2014.
fCombined responses to queries about timing, dosage, and route.
gQuestion not asked in September 2013-October 2014.
Table 1 also compares the characteristics of callers before and
after November 2014 when the call center number started to be
printed on the combination pack. As expected, because of the
large population size, all differences were statistically significant
using the chi-square test. After November 2014, a larger
proportion of calls were from pharmacy workers, MR users,
and their relatives, whereas proportionally fewer calls were
from MR users’ husbands and village doctors. After November
2014, more callers reported taking the complete regimen before
calling and proportionally more reported experiencing side
effects, but these trends are likely linked.
Change in Call Center Use Over Time
The brands of MR medications reported to have been purchased
by call center users varied over time, and details of the most
commonly mentioned brands are shown in Table 2. Figure 3
shows the number of calls by type and brand of MR drug over
time, grouped by the brands in Table 2. Before November 2014,
the callers were mainly using 2 brands of misoprostol. When
the call center number was advertised on the packaging of a
combination pack released into the market in November 2014,
an increasing number of calls were related to this brand of the
combination regimen (brand 2). In January 2015, the
combination regimen brand 1 also began to advertise the call
center number on its packaging (although the brand had been
on the market since February 2013), and there was a
corresponding increase in calls. The call center also received
calls about products that do not have the call center number on
the packaging, reflecting the promotion of the call center through
other channels including in-pharmacy posters and danglers.
Time series plots showed that over the 4-year reference period,
the mean number of MR users who reported they were under
20 years increased. Over time, there was a steady decrease in
calls from husbands of MR users, and slight increases in calls
from MR users and pharmacists or pharmacy workers. There
was a noticeable increase in the proportion of callers who
reported having taken the complete regimen and decrease in
those who had called the call center when they had only started
the regimen.
ITS analyses using November 2014 as the intervention point
are shown in Table 3 as regression results and Figure 4 as plots
for selected outcomes (plots for all outcomes in Table 3
available on request). Table 3 shows that there were significant
differences in the trends in the number of calls at November
2014 (the last column) related to several factors. After
November 2014, an upward trend began in the number of calls
where the user had taken the complete regimen, and likely
related to this, there were similar post-November 2014 upward
trends in calls concerning MR users experiencing side effects
and enquiring about pain medication. There were downward
trends post-November 2014 in the number of calls asking about
dosage and regimen and asking for information on side effects.
There were no significant trend changes in the caller age and
types of callers and in the number of calls regarding suspected
complications.
Table 2. Details of the most commonly mentioned menstrual regulation medications.
Date call center number first printed on productDate registered in BangladeshProduct
September 2011September 2011Misoprostol brand 1
Not printed2002Misoprostol brand 2
January 2015February 2013Combination brand 1
October 2014October 2014Combination brand 2
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Figure 3. Number of calls by month according to brand of menstrual regulation drug purchased (September 2013-August 2016).
Table 3. Interrupted time series regression results comparing the number of calls pre- and post-November 2014, overall, by type of caller, and reason
for calling.
Change in time trend after
November 2014 (95% CI)
Step change at November
2014 (95% CI)
Time trend (calls per month)
before November 2014
(95% CI)
Mean calls per
month at start of
time series
Characteristic of the call or caller
−1.6 (−0.73 to 70.0)1866.6 (1064.5 to 2668.8)115.0 (87.3 to 142.8)2641.5Overall
Type of caller
2.8 (−15.5 to 21.2)277.5 (10.6 to 544.5)41.7 (32.2 to 51.2)352.2Pharmacist or pharmacy worker
16.5 (−21.3 to 54.5)632.7 (60.8 to 1204.8)13.1 (−5.5 to 31.8)732.4Menstrual regulation (MR) user
(woman)
Reported age of MR user (years)
22.3 (−2.8 to 47.4)391.8 (75.0 to 708.6)35.8 (28.1 to 43.7)362.7<20
MR user had taken drug before call
30.9 (4.4 to 57.4)360.8 (46.8 to 674.8)11.6 (3.1 to 20.1)362.7Taken complete regimen
Reason for calling about MR
−36.9 (−96.8 to 23.7)1510.5 (771.1 to 2250.0)95.6 (77.2 to 114.0)1775.7Correct MR dosage and regimen
−36.5 (−96.8 to 23.7)1490.5 (754.2 to 2226.9)97.8 (79.2 to 116.5)1733.8Information on side effects and
complications
36.9 (10.7 to 63.2)300.3 (−24.2 to 624.9)9.7 (2.4 to 16.9)503.5Experiencing side effects
3.7 (−4.3 to 11.6)70.6 (−23.3 to 164.6)4.5 (3.4 to 5.7)24.2Caller suspects complications
15.1 (3.3 to 26.9)133.1 (−11.0 to 278.2)2.0 (−4.8 to 8.8)256.2Questions about pain medication
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Figure 4. Plotted time series data and fitted regression lines considering pre- and postintroduction of the combination regimen (November 14) for
selected outcomes.
Misoprostol-Only and Combination Regimen Callers
Table 4 compares the characteristics and reasons for calling
between callers who had purchased misoprostol-only versus
the combination pack (data from November 2014 to August
2016). There was little difference in the age profile of the 2
types of callers. Combination pack callers were more likely to
be MR users themselves (26.9% vs 22.0%) and less likely to
be the husbands of MR users (18.0% vs 21.2%). Combination
pack purchasers were more likely than misoprostol-only
purchasers to call after taking the complete regimen (19.0% vs
16.3%), to have called for information about dose or timing
(73.6% vs 70.8%), or to say they were experiencing side effects
(19.6% vs 18.1%). Misoprostol-only callers were more likely
to need information about pain medication (8.7% vs 7.2%),
think they had taken the wrong dose (3.6% vs 2.1%), or need
to access the clinic or hospital (7.1% vs 5.0%). Combination
pack callers were more likely to call citing bleeding as a side
effect (6.3% vs 2.8%), which may be because more had taken
the complete regimen or may reflect underdosing of misoprostol
only users.
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Table 4. Differences between combination drug and misoprostol-only purchasers (November 2014-August 2016, N=169,619).
P valueMisoprostol only
(n=74,210), n (%)
Combination regimen
(n=95,447), n (%)
Characteristic of call or caller
.001Type of caller
481 (0.65)523 (0.55)Pharmaceutical representative
18,207 (24.54)21,993 (23.05)Pharmacist or Pharmacy worker
13,740 (18.52)17,920 (18.78)Village doctor
16,315 (21.99)25,648 (26.88)Menstrual regulation (MR) user (woman)
15,741 (21.22)17,156 (17.98)Husband of MR user
5411 (7.29)6919 (7.25)Mother and other relative of MR user
4236 (5.71)5163 (5.41)Friend of MR user
63 (0.08)103 (0.11)Don’t know, refuse and missing
.001Reported age of MR user (years)
18,232 (24.57)25,625 (26.85)<20
26,973 (36.35)32,454 (34.00)20-24
15,799 (21.29)20,127 (21.09)25-29
10,593 (14.27)13,748 (14.40)30 or older
2613 (3.52)3493 (3.66)Don’t know, refuse and missing
.00132,821 (44.23)42,855 (44.90)Repeat callera
.001MR user had taken drug before calling
12,106 (16.31)18,099 (18.96)Taken complete regimen
6947 (9.36)5097 (5.34)Started the regimen
52,519 (70.77)70,224 (73.57)Not taken
2638 (3.55)2027 (2.12)Don’t know and other
Specific MR-related queryb
.00170,677 (95.24)93,468 (97.93)Whether misoprostol or combination pack used for MR
.00152,523 (70.78)70,224 (73.57)Correct MR dosage and regimen
.00152,523 (70.78)70,224 (73.57)Information on side effects or complications
.00113,422 (18.09)18,750(19.64)Experiencing side effects
.0012783 (3.75)2942 (3.08)Caller suspects complications
.0012650 (3.57)2024 (2.12)Thinks they have taken the wrong dosec
.0016431 (8.67)6854 (7.18)Questions about pain medication
.0015245 (7.07)4739 (4.97)Accessing clinic or hospital
Type of side effect reportedd
.01508 (0.68)757 (0.79)Nausea
.0011308 (1.76)1489 (1.56)Vomiting
.033376 (4.55)4136 (4.33)Diarrhea
.001589 (0.79)1937 (2.03)Headache
.0016379 (8.60)6850 (7.18)Cramps
.0012041 (2.75)5981 (6.27)Bleeding
.0012377 (3.20)2009 (2.10)Fever
aQuestion introduced in July 2013.
bMultiple responses are allowed, so percentage may sum to more than 100%.
cNo data available in September 2013-October 2014.
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dQuestion introduced in July 2013.
Discussion
Principal Findings
This study analyzed the usage patterns of a call center in
Bangladesh that was established to reduce harm from potential
incorrect use of MR medications, and the findings point to the
effectiveness and feasibility of this approach. Consistent with
findings from surveys of pharmacy workers undertaken in 2011
[19] and in 2013 [21], the results suggest that misoprostol and,
more recently, the combination regimen are being used widely
for MR but that gaps in knowledge exist among both end users
and drug providers. There was a high and increasing number
of calls about MR over the 4-year period, suggesting that the
call center addressed an unmet need for information. MR users
and their relatives, and providers or sellers of medications most
often called for information about the correct dosage, and the
potential side effects or complications of MR medications.
Changes in the types of drugs available for MR were associated
with changes in call center use. The high call volume and high
proportion of repeat calls suggests that the call center method
of communicating information on this stigmatized issue is
acceptable to both providers and end users and their relatives,
including younger women, and that mHealth initiatives can
successfully reach women, providers, and their relatives of
different ages and geographical areas of Bangladesh [29].
This study adds to the evidence on call center support for
maternal and reproductive health issues [12,29,30] by detailing
the experience in Bangladesh, where availability of information
on MR medications remains insufficient.
Improving the quality of information available to women who
purchase mifepristone or misoprostol from pharmacies is a
challenge, and although pharmacy worker–focused interventions
such as training and detailing have had some impact on
pharmacy provision [3,31,32], these interventions can be
expensive and difficult to provide at scale. In addition, they
may not be appropriate in contexts where staff turnover at
pharmacies is high [2]. Our analysis suggests that in addition
to making information available to the end user directly, a call
center intervention can make information available to those
selling MR medications or advising local communities on health
issues. The potential to reduce harm from incorrect use of MR
medications is reflected in the fact that the majority of callers
made contact before taking the products. That nearly one-fifth
of calls were from village doctors deserves further investigation
on the role of these health providers on providing MR and
reproductive health care. Although a lot of current research
concentrates on pharmacies as frontline providers, village
doctors may be another way of improving access to quality care
in hard-to-reach populations.
An important function of the call center is to provide referral
information to women experiencing complications after taking
misoprostol for MR. The WHO recommended a
misoprostol-only MR regimen of 800 mcg taken sublingually
up to 3 times at 6-, 12-, and 24-hour intervals [33] has been
found to have an 85% to 90% effectiveness rate [34,35]. If
callers to the MSB call center were representative of
misoprostol-only MR users, we would therefore expect a
minimum of 15% of women to have experienced an incomplete
MR. Of misoprostol-only callers to the call center, 2.7% reported
that the end user was experiencing suspected complications, all
of which were suspected incomplete procedures. This suggests
that most women who are experiencing complications or
incomplete MR are not calling the call center for support. It is
possible that these women may be going directly to clinics or
back to the drug seller to receive follow-up care, but further
research into the care-seeking patterns of women who
experience incomplete MR after using misoprostol alone is
required.
Unsurprisingly, the introduction of the combination pack into
the market was followed by a decline in the number of calls
regarding misoprostol-only MR and an increase in calls about
the combination regimen. As increases in calls were clearly
linked to when various brands started to include the call center
number on the packaging, it also suggests the efficacy of this
technique to publicize call centers as a source of support for
women self-administering MR medications. Unlike misoprostol,
the combination regimen is packaged for MR with instructions
on use. ITS analysis showed that after the call center number
started to be printed on combination regimen packaging,
significantly more calls were made about MR users who had
taken the complete regimen and who were experiencing side
effects and wanted information on pain medication. Conversely,
downward trends were seen after November 2014 for enquires
about dosage, regimen, and asking for information on side
effects, which is logical given that the combination regimen
pack prints usage instructions. This suggests that after the
introduction of the combination regimen to the market, callers
more often called later in the MR process and with different
kinds of queries.
Our sample is likely not representative of all women who are
accessing MR medications through pharmacies in Bangladesh,
and preliminary analyses suggest that call center users may be
younger than the general population of MR users in Bangladesh.
As a crude comparison of age distribution, we used the 2014
Bangladesh Demographic and Health survey (DHS) [9] to
calculate the age distribution of women who reported having
used MR is the previous 3 years (N=538) and compared this
with the reported age distribution of MR users reported to call
center operators. The age profile of recent MR users from the
DHS is notably older, with the majority (87.7%) being 25 years
and older; and the majority of users reporting being between
30 and 34 years. Although the differing age distributions could
be partly related to the DHS reference period of 3 years or
underreporting of MR by younger women in the DHS, it could
also suggest that MR users contacting the call center may be
on average younger than the general population of MR users.
This may reflect younger women being more likely to access
MR using medications, to access it through pharmacies, to have
a query about it, and to use the call center. Younger women
may also face additional barriers to accessing MR facility
services due to age, childbearing, and partnership norms [36].
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Limitations
Our study has some limitations and implications for further
research. We collected limited data on repeat callers, and these
were not linked, so the characteristics of the 45% of calls who
are repeat callers are overrepresented in the data. It would be
useful to understand more about repeat callers: why they called
more than once and the duration between calls, for example.
Further information is also needed about non-MR callers, as
the numbers of these have been increasing and now account for
a quarter of calls. This could suggest a further need for
accessible advice for other reproductive health issues such as
family planning or a change in the way the call center is
promoted to better address other reproductive health needs.
Further research is needed to understand the impact of this
intervention on provider provision practices and client outcomes
such as complete MR, use of post-MR family planning, and
access to appropriate treatment for complications.
Conclusions
Evidence has demonstrated that availability of misoprostol can
lead to a decrease in the rate and severity of abortion
complications [4]. To achieve this, a comprehensive harm
reduction approach is needed; the key components include
procuring and distributing high-quality drugs, ensuring training
and support mechanisms for providers, building effective referral
mechanisms for complication management, and addressing the
need for postabortion family planning. This study demonstrates
that a call center can form an important part of such a harm
reduction package by providing information to providers and
MR users and advising on post-MR family planning.
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